+

WO1986000929A1 - Molecule d'adn recombinant, microorganismes transformes et procede de production de penicilline v amidase - Google Patents

Molecule d'adn recombinant, microorganismes transformes et procede de production de penicilline v amidase Download PDF

Info

Publication number
WO1986000929A1
WO1986000929A1 PCT/SE1985/000287 SE8500287W WO8600929A1 WO 1986000929 A1 WO1986000929 A1 WO 1986000929A1 SE 8500287 W SE8500287 W SE 8500287W WO 8600929 A1 WO8600929 A1 WO 8600929A1
Authority
WO
WIPO (PCT)
Prior art keywords
amidase
penicillin
dna
recombinant dna
dna molecule
Prior art date
Application number
PCT/SE1985/000287
Other languages
English (en)
Inventor
Sten Gatenbeck
Björn Nilsson
Anders Olsson
Matthias Uhlen
Original Assignee
Sten Gatenbeck
Nilsson Bjoern
Anders Olsson
Matthias Uhlen
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Sten Gatenbeck, Nilsson Bjoern, Anders Olsson, Matthias Uhlen filed Critical Sten Gatenbeck
Publication of WO1986000929A1 publication Critical patent/WO1986000929A1/fr
Priority to DK141586A priority Critical patent/DK141586D0/da

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/63—Introduction of foreign genetic material using vectors; Vectors; Use of hosts therefor; Regulation of expression
    • C12N15/74—Vectors or expression systems specially adapted for prokaryotic hosts other than E. coli, e.g. Lactobacillus, Micromonospora
    • C12N15/75—Vectors or expression systems specially adapted for prokaryotic hosts other than E. coli, e.g. Lactobacillus, Micromonospora for Bacillus
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N9/00—Enzymes; Proenzymes; Compositions thereof; Processes for preparing, activating, inhibiting, separating or purifying enzymes
    • C12N9/14—Hydrolases (3)
    • C12N9/78—Hydrolases (3) acting on carbon to nitrogen bonds other than peptide bonds (3.5)
    • C12N9/80—Hydrolases (3) acting on carbon to nitrogen bonds other than peptide bonds (3.5) acting on amide bonds in linear amides (3.5.1)
    • C12N9/84—Penicillin amidase (3.5.1.11)

Definitions

  • the present invention relates to recombinant deoxy- ribonucleic acid with codes for penicillin V amidase or an active derivative thereof as well as a process for the pre ⁇ paration thereof.
  • the invention also relates to a transfor- mant microorganism including such recombinant deoxyribonucleic acid and the preparation thereof.
  • the invention further relates to the use of such a transformant microorganism for the production of penicillin .V amidase or an active derivative thereof.
  • Penicillin amidases, (E.C.3.5.1.11) catalyzing the hydrolysis of penicillins to 6-aminopenicillanic acid (6-APA) and the specific side chain, are widely distributed among microorganisms (see e.g.
  • Penicillin V amidases specific for phenoxymethyl- penicillin, are mainly found in fungi, although several strains of Bacillus species, including B. sphaericus (see Carlsen and Emborg ), produce penicillin V amidase.
  • a recombinant DNA molecule which includes a deoxyribonucleotide sequence con ⁇ taining the genetic information for penicillin V amidase.
  • a recombinant DNA molecule or so-called hybrid vector can be introduced into any suitable host microorganism, which can then be cultured to produce the desired enzyme material.
  • a transformed microorganism can be obtained, which will be nonpathogenic and also will produce substantial quantities of penicillin V amidase. Due to self- replication of the vector DNA in the host cells producing an amplified quantity of genes coding for penicillin V amidase, the production of this amidase will be substantially greater than that from hitherto used B. sphaericus strains.
  • the relatively new recombinant DNA technology or genetic engineering referred to above permits the introduction of a specific nucleotide sequence coding for a desired protein or polypeptide into a bacterial or other appropriate host cell thereby conferring the desired property thereto.
  • the DNA may
  • transformant microorganisms may comprise the steps of producing a double-stranded DNA sequence coding for the desired protein or polypeptide; link ⁇ ing the DNA to an appropriate site in an appropriate cloning vehicle or vector to form recombinant DNA molecules, some of which will contain the desired protein coding gene; transform ⁇ ing an appropriate host microorganism with the recombinant DNA molecules; screening the resulting clones for the presence of the protein or polypeptide coding gene by suitable means; and selecting and multiplying one or more of the positive clones.
  • one or more re- or subclonings may be performed, comprising the extraction and cleavage of the protein coding DNA, insertion of the cleaved fragments into a second cloning vehicle or vector and screening for the presence of the protein or polypeptide coding gene.
  • the aim of the present invention is to achieve a pro ⁇ duction of penicillin V amidase with the use of recombinant DNA technology. This has been accomplished by the finding of a DNA sequence of at least partially unknown structure, i.e. the DNA sequence coding for penicillin V amidase in a suitable host, and the separation of the sequence from a highly complex mixture of DNA sequences, as will be further explained below.
  • the recombinant DNA technology offers the possibility of preparing microorganisms capable of producing not only penicillin V amidase but also modified enzyme products having penicillin V amidase activi ⁇ ty, such as fragments of penicillin V amidase or fusion proteins which consists of penicillin V amidase and another protein or oligopeptide, as also will be described in more detail hereafter.
  • one aspect*of the present invention relates to a novel microorganism transformed by recombinant DNA technolo- gy, which microorganism is capable of producing penicillin V amidase.
  • the invention also relates to the preparation of such a microorganism through transformation of a host organism with a recombinant DNA molecule.
  • Another aspect of the invention relates to such a re- combinant DNA molecule, which comprises at least one DNA sequence coding for penicillin V amidase, and to a process for its preparation.
  • Still another aspect of the invention relates to a process for preparing penicillin V amidase by culturing a transformed microorganism of the invention.
  • penicillin V amidase means any protein acromolecule which can catalyze the hydro ⁇ lysis of phenoxymethyl penicillin to 6-aminopenicillanic acid (6-APA) and phenoxy-acetic acid.
  • the expression comprises penicillin V amidase molecules which may have a non-penicillin V amidase peptide sequence linked thereto, e.g. due to insertion of chemically synthetized oligonucleo- tides when constructing the cloning vehicle.
  • Nucleotide A monomeric unit of DNA or RNA consisting of a sugar moiety (pentose) , a phosphate, and a nitrogenous hetero- cyclic base.
  • the base is linked to the sugar moiety via the glycosidic carbon (1 • carbon of the pentose) and that combi ⁇ nation of base and sugar is a nucleoside.
  • the base characte- rizes the nucleotide.
  • the four DNA bases are adenine ("A"), guanine ("G”), cytosine (“C”) and thymine (“T”).
  • the four RNA bases are A, G, C and uracil (“U”).
  • DNA sequence A linear series of nucleotides connected one to the other by phosphodiester bonds between the 3' and 5' carbons of adjacent pentoses.
  • Codon A DNA sequence of three nucleotides (a triplet) S which encodes through messenger RNA "mRNA") an amino acid, a translational start signal or a translational termination signal.
  • mRNA messenger RNA
  • the nucleotide triplets TTA, TTG, CTT, CTC, CTA and CTG encod-e for the amino acid leucine ("Leu"), TAG, TAA and TGA are translational stop signals and ATG is 10 a translational start signal.
  • Plasmid A non-chromosomal double-stranded DNA sequence comprising an intact "replicon" such that the plasmid.is replicated in a host cell.
  • the characteristics of that or- 15 ganism are changed or transformed as a result of the DNA of the plasmid.
  • Tet tetracycline resistance
  • a host cell transformed by a plasmid is called a "trans- 20 formant”.
  • Phage or Bacteriophage Bacterial virus many of which in ⁇ clude DNA sequences encapsidated in a protein envelope or coat.
  • Cloning Vehicle A plasmid, phage DNA or other DNA sequence 25. which is able to replicate in a host cell, characterized by one or a small number of endonuclease recognition sites, or restriction sites, at which its DNA sequence may be cut in a determinable fashion without attendant loss of an essential biological function of the DNA, e.g., replication, production 0 of coat proteins or loss of promoter or binding sites, and which contains a marker suitable for use in the identifica ⁇ tion of transformed cells, e.g., tetracycline resistance or ampicillin resistance.
  • a cloning vehicle is also known as a vector.
  • Host An organism which on transformation by a cloning ve ⁇ hicle enables the cloning vehicle to replicate and to accomp ⁇ lish its other biological functions, e.g., the production of polypeptides or proteins through expression of the genes of a plasmid.
  • Cloning The- process of obtaining a population of organisms or DNA sequences derived from one such organism or sequence by asexual reproduction.
  • Expression The process undergone by a gene to produce a polypeptide or protein. It is a combination of transcription and translation.
  • Transcription The process of producing mRNA from a gene.
  • Translation The process of producing a protein or poly- peptide from mRNA.
  • Promoter The region of the DNA of a gene at which RNA poly- merase binds and initiates transcription.
  • a promoter is loca ⁇ ted before the ribosome binding site of the gene.
  • Ribosome Binding Site The region of the DNA of a gene which codes for a site on mRNA which helps the mRNA bind to the ribosome, so that translation can begin. The ribosome binding site is located after the promoter and before the translational start signal of the gene.
  • Gene A DNA sequence which encodes, as a template for mRNA, a sequence of amino acids characteristic of a specific poly ⁇ peptide or protein.
  • a gene includes a promoter, a ribosome binding site, a translational start signal and a structural DNA sequence.
  • the gene also includes a signal DNA sequence.
  • Expression Control Sequence A DNA sequence in a cloning vehicle that controls and regulates expression of genes of the cloning vehicle when operatively linked to those genes.
  • Signal DNA Sequence A DNA sequence within a gene for a polypeptide or protein which encodes, as a template for mRNA, a sequence of hydrophobic amino acids at the amino terminus of the polypeptide or protein, i.e., a "signal sequence” or "hydrophobic leader sequence” of the polypeptide or protein.
  • a signal DNA sequence is located in a gene for a polypeptide or protein immediately before the structural DNA sequence of the gene and after the translational start signal (ATG) of the gene.
  • a signal DNA sequence codes for the signal sequence of a polypeptide or protein which (signal sequence) is characteristic of a precursor of the polypeptide or pro ⁇ tein.
  • Precursor A polypeptide or protein as synthetized within a host cell with a signal sequence.
  • Downstream and Upstream On a coding DNA sequence downstream is the direction of transcription, i.e. in the direction 5 from 5 r to 3*. Upstream is the opposite direction.
  • Recombinant DNA Molecule or Hybrid DNA A molecule consis ⁇ ting of segments of DNA from different genomes which have been joined end-to-end " outside- of living cells and have the capacity to infect some host cell and be maintained therein.
  • Structural DNA Sequence A DNA sequence within a gene which encodes, as a template for mRNA, a sequence of amino acids characteristic of a specific mature polypeptide or protein, i.e., the active form of the polypeptide or protein.
  • One aspect of the invention is to provide a recombinant 15 DNA molecule comprising a deoxynucleotide sequence coding for penicillin V amidase or all active derivatives thereof.
  • the origin of said deoxynucleotide sequence is not critical to the invention, but any source can be used, including natural, synthetic or semi-synthetic DNA sources.
  • the source 20 of DNA coding for penicillin V amidase is in most cases a bacterial donor, such as a strain of B. sphaericus, although synthetically produced molecules also are possible.
  • a suitable cloning vehicle or 25. vector may be cleaved by means of a restriction enzyme and the DNA sequence or fragment coding for the penicillin V amidase inserted into the cleavage site to form a recombinant DNA molecule.
  • This general procedure is known per se and various techniques or methods to link the DNA sequence to 0 the cleaved cloning vehicle are described in the literature
  • B. sphaericus chromosomal DNA is used as the source of the deoxynucleotide sequence to be inserted into the selected vector, it may be obtained by treating the B. sphaericus strain with the enzyme lysozyme to form proto-.
  • a DNA preparation 5 plasts, which are then lysed and the DNA extracted and isolat ⁇ ed to form a DNA preparation.
  • the DNA preparation can be cleaved into fragments of an appropriate size.
  • the transformed cells which contain either a vector or a vector/Bacillus DNA combination, can be selected on the basis of a suitable marker included in the vector, e.g. antibiotic resistance, such as tetracycline resistance.
  • a suitable marker included in the vector e.g. antibiotic resistance, such as tetracycline resistance.
  • antibiotic resistance such as tetracycline resistance.
  • a "gene bank" of the B. sphaericus strain can be obtained, consisting of a great number, e.g. several thousands, of clones which contain Bacillus DNA.
  • the clone or clones containing the penicillin V amidase producing gene can then be found by any suitable assay for penicillin V amidase activity, e.g. sensitivity to the product 6-APA.
  • fragments of the DNA of penicillin V amidase producing clones may be subcloned into the same or another host micro ⁇ organism.
  • the cloning vehicles or vectors that can be used in the present invention depend i.a. on the nature of the host cell to be transformed, i.e. whether it is a bacterium, yeast or other fungi, etc.
  • Useful cloning vehicles may, for example, consist of segments of chromosomal, non-chromosomal and synthetic DNA sequences, such as various known bacterial plasmids, e.g., plasmids from E.
  • coli including pBR 322 and their derivatives, phage DNA, such as derivatives of phage lambda, vectors derived from combinations of plasmids and phage DNAs, yeast plasmids, specially constructed composite plasmids, etc.
  • phage DNA such as derivatives of phage lambda
  • vectors derived from combinations of plasmids and phage DNAs yeast plasmids, specially constructed composite plasmids, etc.
  • the particular selection of cloning vehicle with regard to a particular host may be made by a person skilled in the art, who also can select the site for the insertion of the DNA within each specific cloning vehicle, the cleavage sites being dependent on the restriction enzyme used. It is not necessary for a cloning vehicle useful in this invention to have a restriction site for insertion of the chosen DNA fragment, but the cloning vehicle could instead be joined to the fragment by alternative means, which 8
  • Hosts to be used in the present invention include bacterial hosts, such as strains of Escherichia, Bacillus, Staphylococcus, and Streptomvces, e.g. E. coli and Bacillus subtilis, yeasts and other fungi, plant cells in culture or other hosts. Due to its non-pathogenic nature the soil-bacterium Bacillus subtilis is considered as particularly useful as ' a final host in the present invention. It is, however, also within the scope of the present inven- tion to transform already penicillin V amidase producing strains of e.g.
  • B.sphaericus with the penicillin V amidase coding recombinant molecule of the invention to multiply the number of penicillin V amidase coding genes in the B.sphaericus cells.
  • Yeast (whose genetics is fairly well known) is also a preferred final host to be transformed into a penicillin V amidase producing microorganism in accordance with the present invention.
  • the promoter sequence of the donor Bacillus strain into the cloning vehicle together with the penicillin V amidase coding sequence. This is the case when e.g. the whole penicillin V amidase coding gene, from promoter to the stop codon, of the Bacillus strain is inserted into the cloning vehicle.
  • Other promoters may also be used, such as the promoter of a naturally occurring vector or of a vector modified by the insertion of strong external promoter.
  • DNA coding for an active derivative of penicillin V amidase as defined above may be obtained by introducing site specific changes in the DNA sequence coding for penicillin V amidase. It is also possible to use the technique called gene fusions (described i.a. by Uhlen et al ) in which the coding sequence of two or more genes are spliced together to form a combined gene which on expression in a suitable host organism will produce a fusion product wherein the separate proteins or polypeptides coded by the respective genes are fused together into a single molecule.
  • gene fusions described i.a. by Uhlen et al
  • gene fusions are.used to combine a DNA sequence coding for penicillin V amidase activity with a DNA sequence coding for a desired protein or polypeptide into a functional gene capable of expressing the fusion product of said desired protein or polypeptide and the penicillin V amidase.
  • the penicillin V amidase product produced according to the present invention can be recovered by conventional techniques.
  • the protein, or polypeptide product is retained within the cell, as is the case when no signal peptide for the product is synthetized, the cells must be ruptured before isolation can be effected.
  • Such rupture of the cell walls may e.g. be done by pressing, ultras ⁇ nication, homogenization, shaking with glass-beads, etc.
  • Fig. 1 is a SPS-PAGE of minicell preparations and purified penicillin V amidase from B. sphaericus. The samples were applied to the same gel and the gel divided in two halves and bands visualized by auto radiography and Comassie staining, respectively.
  • Fig. 2 is the pH optimum of penicillin V amidase.
  • Fig. 3 is a Lineweaver-Burke plot for penicillin V amidase ( * ) , with 50 mM 5-APA ( o ) and with 20 mM phenoxy- acetic acid ( + ) .
  • Fig. 4 is a schematic presentation of plasmid construct ⁇ ion used to subclone the gene coding for penicillin V amidase. Thick lines indicate plasmid vectors and thin lines indicate inserted fragment. Relevant restriction sites are indicated. In the Examples the starting the starting materials, buffers, cell media and routine method steps were as follows. 10
  • the bacterial strains and plasmids used are listed in the following table.
  • Bacillus sphaericus Penicillin V amidase ATCC 14577 producer Bacillus sphaericus Penicillin V amidase ATCC 14577 producer
  • Luria-broth 10 g Difco tryptone, 5 g Difco yeast extract, 0.5 g NaCl, 2 ml 1M NaOH; adjusted to pH 7.0 with 1M NaOH; 10 ml 201 glucose added after autoclaving.
  • LA-medium Luria-broth supplemented with 11 Difco agar.
  • Tris-EDTA buffer (TE) 0.001 M EDTA and 0.01 M Tris (pH 7.8)
  • NY-medium 8 g Difco nutrient broth, 5 g Difco yeast extract, 5 ml 1M MgSO. and 2 ml 10 ml mM MnCl 2 added after autoclaving.
  • Antibiotics were obtained from Pfizer (tetracycline), Astra, Sweden (ampicillin) , Sigma (chloramphenicol) and Fermenta, Sweden (penicillin V, 6-APA and phenoxyacetic acid). S-methionine was obtained from New England Nuclear.
  • Transformations Transformation of E. colj ⁇ C12, with plasmid DNA, was performed exactly as described by Morrison .
  • the 20 transformed cells were selected in a conventional manner on plates by plating for single colonies on LA plates containing suitable antibiotics, i.e. 10 ⁇ g/ml of tetracycline.
  • Proto ⁇ plasts of _B. subtil-is were transformed exactly as described by Chang and Cohen .
  • DNA fragments All DNA fragments were ligated at 14°C over-night with T4 DNA ligase purchased from New England Bio Labs, Waltham, MA., USA, in a buffer recommended by the supplier.
  • Agarose gel electrophoresis 0. 7% agarose gel electro- phoresis for separating cut plasmid fragments, supercoiled plasmids, and DNA fragments 1000 to 10,000 nucleotides in
  • Polyacryla ide gel electrophoresis 131 polyacrylamide gel electrophoresis for the separation of proteins of molecular weights of 5,000 to 120,000 was performed exactly as described by Laemmli .
  • Chromosomal DNA from B. sphaericus was prepared by total lysis followed by sodium dodecyl sulfate (SDS) treatment and extraction with phenol.
  • the DNA was frac ⁇ tionated after digestion with restriction enzyme on a sucrose gradient 10-30 (w/v) in TE buffer (according to Maniatis et al. ) containing 1 M NaCl.
  • Plasmid DNA from E. coli was prepared by the alkaline lysis method as described by Birnboim and Doly ⁇ .
  • Plasmids from B. subtilis were prepared with a modified alkaline lysis method as follows.
  • a 5 ml overnight culture was centrifuged and the pellet resuspended in a total volume of 500 yl lysozyme solution (0.3 M sucrose, 25 mM Tris/HCl pH 8.0, 0.02 bro phenolblue, 25 mM EDTA and 2 mg/ml lysozyme).
  • 500 yl lysozyme solution 0.3 M sucrose, 25 mM Tris/HCl pH 8.0, 0.02 bro phenolblue, 25 mM EDTA and 2 mg/ml lysozyme.
  • the suspension was incubated for 30 min at 37°C.
  • 2S0 ⁇ l of NaOH/SDS solution 0.3 M NaOH and 2 SDS
  • the solution was then extracted with 80 ⁇ l phenol/ chloroform, (500 g phenol, 500 ml chloroform and 200 ml water) , the phases separated and the aqueous phase containing plasmid DNA precipitated with 0.3 M sodium acetate and 1 volume isopropanol.
  • E. coli. clones carrying B.sphaericus DNA were replicated to LA plates and incubated overnight. They were then overlayed with 5 ml of soft agar containing Serratia arcesens (0.5 ml of an over 13
  • Minicells were puri ⁇ fied from the E. coli strain M2141 by two sucrose gradient centrifugations as described by Kennedy . Labelling of mini- cells with 35S -methionine was carried out in minimal medium 0 supplemented with glucose, thiamine and methionine assay medium
  • Assay of penicillin V amidase activity Cells were grown in liquid medium containing the appropriate antibiotic and har ⁇ vested after overnight growth. The cells were resuspended in S 1/10 vol of 0.1 M sodium citrate buffer (pH 5.8) and dis ⁇ rupted by sonication. The homogenate was centrifuged and the supernatant used for assay of penicillin V amidase activity.
  • the standard assay mixture (total volume 500 yl) contained 3% (w/v) penicillin V (potassium salt) in 0.1 M sodium citrate 0 buffer pH 5.8. The reaction was started by adding enzyme
  • 6-APA was also identified by thin layer chromatography according to
  • B. sphaericus was grown in a 12 1 fermentor (Chemoferm) in NY-medium without regulation of pH with an aeration of 1 vvm, stirring at 700 rpm and at temperature of 30°C. After 10-11 hrs of growth, the cells were harvested in a CEPA centrifuge. The yield was 85 g wet weight from 10 1 culture medium. Cell paste was suspended (16. g wet weight/60 ml) in 50 mM potassium phosphate buffer (pH 6.8) and the cells were disrupted by soni- cation for 5x45 s at 0°C (70W).
  • the extract was centrifugated at 15 OOOxg for 30 min at 4°C and the suspernatant used for purification of the enzyme essentially as described by Carlsen and Emborg . Following a 401 ammonium sulfate precipitation the enzyme was precipitated with 70 ammonium sulfate.
  • the pre ⁇ cipitate was resuspended in a small volume " of 0.1 M Tris/HCl and 10 mM EDTA pH 8.0 and placed on a Sephadex G-200 gel column equilibrated with 0.1 M Tris/HCl, 10 mM EDTA pH 8.0.
  • the column was eluted with the same buffer and fractions with high activity were pooled and immediately chromatographed on a DEAE-Sephadex A-50 column. Analysis of the purified enzymes: The protein concentration was measured by the method of Bradford with bovine albumin as standard. Polyacrylamide gel electrophoresis (SDS-PAGE) was carried out as described by Laemmli . Isoelectric focusing was carried out using LKB ampholine PAGplates pH 4.0-6.5. The molecular weight of the native enzyme was determined by HPLC using a LKB 2135 Ultropac TSK column packed with G3000 SYI gel. The solvent was 50 mM potassium phosphate buffer pH.7.0 with 0.2 M NaCl.
  • One unit (U) is defined as the amount of enzyme which catalyzed the formation of 1 ⁇ mol of 6-APA per min. Determined according to Ko ⁇ feld1
  • the purity of the final preparation was analysed by SDS- -PAGE (see Fig. 1 ) revealing a major, band with a molecular weight of 35 000 , corresponding to more than 95! of the total protein content .
  • the molecular weight of the native enzyme was determined using two independent methods . Gradient electrophoresis followed by enzyme staining gave one band with a molecular weight of 140 000 and gel filtration in a HPLC-system gave a molecular weight of 135 000. This suggests that the native enzyme consists of four identical subunits , each with a molecular weight of 35 000.
  • the isoelectric point of the native enzyme was determined by isoelectric focusing which gave a major band corresponding to a pi of 4.8.
  • the enzyme activity at different pH values was mea ⁇ sured giving the pH-profile shown in Fig. 2 with an optimum around pH 5.8.
  • the kinetic properties are shown in Fig. 3.
  • the K of fi mM is significantly lower than that previously published .
  • both enzyme products inhibit the reaction.
  • Phenoxyacetic acid is a non-competitive inhibi ⁇ tor with K. of 25 mM and 6-APA acts as a competitive inhibitor Cloning and expression of the gene for penicillin V amidase:
  • a gene bank of B. sphaericus DNA was constructed. Chromo ⁇ somal DNA was partially digested with Mbol and fractionated by sucrose gradient centrifugation (10-30%) and fractions containing approximately 10 kilobases (kb) fragments were mixed and ligated with Bell-cleaved pTR262 21 and used to transform E. coli HB10T. About 2200 tetracycline resistant clones were transferred to microtiterplates, grown overnight, and stored in a freezer at -80°C. Approximately 1000 clones were screened with the Serratia overlay technique and two positive clones, pOH2 and pOH3, were found.
  • FIG. 4 A restriction map of pOH3, the smaller of the two plasmids, is shown in Fig. 4.
  • This E. coli strain with the plasmid pOH3 is denomi ⁇ nated PVA-3 and has been deposited at Deutsche Sammelung von Mikroorganismen and given the accession number DSM 2982.
  • the size of the insert in pOH3 was shown to be 9.1 kb.
  • Various subclones were constructed in order to determine the minimum size of inserted DNA that is necessary for amidase activity (Fig. 4).
  • the plasmid pOH31 obtained by digestion with HindiII and religation has no functional amidase activity (Table 3) , in contrast to plasmid pOH35 containing a 2.2.
  • pOH36 kb fragment obtained by digestion with PstI and religation.
  • Clal fragment was removed from pOH35 the activity was lost indicating that all or part of the gene is within this fragment.
  • the resulting plasmid pOH36 was, in all clones isolated, found to be exclusively a dimer (Fig.4).
  • a shuttle vector for B. subtilis and E. coli was constructed by inserting HindiII cleaved pC194 (which has a gene for chloramphenicol acetyl transferase) in the Hindlll site of pOH35. The result ⁇ ing plasmid is called pOH38 (Fig. 4).
  • pOH38 is denominated PVA 38 has been deposited at Deutsche Sammelung von Mikroorganismen and given the accession number DSM 2983.
  • the specific amidase activity in cell-free extracts °f E « coli and B.subtilis are shown in Table 3.
  • the activities in the different E. coli clones are lower than in B.sphaericus B.subtilis (pOH38) gives an expression that is two times higher than in B. sphae.ricus.
  • the plasmids pOH35, pBR322 and pUN101 were used to transform the E.coli minicell strain M2141.
  • the minicells were labelled with S -methionine and the plasmid coded polypeptides were identified after separation on SDS-PAGE (Fig. 1).
  • a protein coded by pOH35 which comigrates with purified penicillin V amidase from B.sphaericus was found. While embodiments of the invention have been presented above, the invention is not restricted thereto, but many variations and modifications of the processes and recombinant 18
  • the invention is, e.g., also meant to encompass cloning vehicles containing more than one separate deoxy- nucleotide sequence coding for the desired protein or poly ⁇ peptide.
  • the invention is intended to comprise also recombinant DNA molecules containing deoxynucleotide sequences, from whatever source obtained, including natural, synthetic or semisynthetic sources, which are related to the " deoxynucleotide sequences coding for penicillin V amidase or an active fragment thereof, as defined above, by muta ⁇ tion, including single or multiple base substitutions, deletions, insertions and inversions.

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Genetics & Genomics (AREA)
  • Chemical & Material Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Organic Chemistry (AREA)
  • Zoology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Wood Science & Technology (AREA)
  • General Engineering & Computer Science (AREA)
  • Biomedical Technology (AREA)
  • Biotechnology (AREA)
  • General Health & Medical Sciences (AREA)
  • Molecular Biology (AREA)
  • Biochemistry (AREA)
  • Microbiology (AREA)
  • Medicinal Chemistry (AREA)
  • Mycology (AREA)
  • Physics & Mathematics (AREA)
  • Biophysics (AREA)
  • Plant Pathology (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Enzymes And Modification Thereof (AREA)

Abstract

Molécule d'ADN recombinant comprenant au moins une séquence d'ADN codant pour la penicilline V amidase ou son derivé et procédé de préparation de cette molécule. L'invention concerne également des microorganismes transformés par ladite molécule d'ADN recombinant ainsi qu'un procédé pour la préparation de tels microorganismes. L'invention concerne en outre un procédé de préparation de penicilline V amidase ainsi que l'amidase produite par ce procédé.
PCT/SE1985/000287 1984-07-31 1985-07-19 Molecule d'adn recombinant, microorganismes transformes et procede de production de penicilline v amidase WO1986000929A1 (fr)

Priority Applications (1)

Application Number Priority Date Filing Date Title
DK141586A DK141586D0 (da) 1984-07-31 1986-03-26 Rekombinant dna-molekyle, fremgangsmaade til fremstilling deraf, mikroorganismer transformeret dermed og fremgangsmaade til fremstilling af penicillin-v-amidase

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
SE8403929A SE8403929L (sv) 1984-07-31 1984-07-31 Rekombinant-dna-molekyl, transformerade mikroorganismer och forfarande for framstellning av penicillin v-amidas
SE8403929-6 1984-07-31

Publications (1)

Publication Number Publication Date
WO1986000929A1 true WO1986000929A1 (fr) 1986-02-13

Family

ID=20356635

Family Applications (1)

Application Number Title Priority Date Filing Date
PCT/SE1985/000287 WO1986000929A1 (fr) 1984-07-31 1985-07-19 Molecule d'adn recombinant, microorganismes transformes et procede de production de penicilline v amidase

Country Status (5)

Country Link
EP (1) EP0190252A1 (fr)
JP (1) JPS61502799A (fr)
DK (1) DK141586D0 (fr)
SE (1) SE8403929L (fr)
WO (1) WO1986000929A1 (fr)

Cited By (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO1995019371A3 (fr) * 1994-01-14 1995-11-16 Solvay Expression de proteines de couches superficielles
US5516679A (en) * 1994-12-23 1996-05-14 Bristol-Myers Squibb Company Penicillin V amidohydrolase gene from Fusarium oxysporum
US6403356B1 (en) 1996-11-05 2002-06-11 Bristol-Myers Squibb Co. Mutant penicillin G acylases
WO2015151118A1 (fr) 2014-04-04 2015-10-08 Council Of Scientific & Industrial Research Pénicilline v acylase recombinante et son procédé de préparation

Citations (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP0021468A1 (fr) * 1979-05-11 1981-01-07 Gist-Brocades N.V. Plasmide, hôte le contenant, sa préparation et utilisation
EP0036259A2 (fr) * 1980-03-10 1981-09-23 Cetus Corporation Méthode, vecteurs et organismes pour des produits génétiques, héterologues, transportés et clonés dans bacillus subtilis et E.coli
EP0060057A1 (fr) * 1981-02-25 1982-09-15 Genentech, Inc. Expression de polypeptides dans des levures
EP0107823A2 (fr) * 1982-10-21 1984-05-09 Gesellschaft für Biotechnologische Forschung mbH (GBF) Séquences d'ADN et structures d'ADN ainsi que procédé de préparation de pénicillinacylase les mettant en oeuvre

Patent Citations (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP0021468A1 (fr) * 1979-05-11 1981-01-07 Gist-Brocades N.V. Plasmide, hôte le contenant, sa préparation et utilisation
EP0036259A2 (fr) * 1980-03-10 1981-09-23 Cetus Corporation Méthode, vecteurs et organismes pour des produits génétiques, héterologues, transportés et clonés dans bacillus subtilis et E.coli
EP0060057A1 (fr) * 1981-02-25 1982-09-15 Genentech, Inc. Expression de polypeptides dans des levures
EP0107823A2 (fr) * 1982-10-21 1984-05-09 Gesellschaft für Biotechnologische Forschung mbH (GBF) Séquences d'ADN et structures d'ADN ainsi que procédé de préparation de pénicillinacylase les mettant en oeuvre

Cited By (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO1995019371A3 (fr) * 1994-01-14 1995-11-16 Solvay Expression de proteines de couches superficielles
US5874267A (en) * 1994-01-14 1999-02-23 Solvay (Societe Anonyme) Expression of surface layer proteins
US5516679A (en) * 1994-12-23 1996-05-14 Bristol-Myers Squibb Company Penicillin V amidohydrolase gene from Fusarium oxysporum
EP0718402A3 (fr) * 1994-12-23 1997-12-17 Bristol-Myers Squibb Company Gène de l'amidohydrolase de penicilline V provenant de fusarium oxysporum
CN1100877C (zh) * 1994-12-23 2003-02-05 布里斯托尔-迈尔斯斯奎布公司 尖孢镰孢的青霉素ｖ酰胺水解酶基因
US6403356B1 (en) 1996-11-05 2002-06-11 Bristol-Myers Squibb Co. Mutant penicillin G acylases
WO2015151118A1 (fr) 2014-04-04 2015-10-08 Council Of Scientific & Industrial Research Pénicilline v acylase recombinante et son procédé de préparation

Also Published As

Publication number Publication date
DK141586A (da) 1986-03-26
DK141586D0 (da) 1986-03-26
EP0190252A1 (fr) 1986-08-13
JPS61502799A (ja) 1986-12-04
SE8403929D0 (sv) 1984-07-31
SE8403929L (sv) 1986-02-21

Similar Documents

Publication Publication Date Title
US4666848A (en) Polypeptide expression using a portable temperature sensitive control cassette with a positive retroregulatory element
US4792523A (en) 3'Expression enhancing fragments and method
US5922583A (en) Methods for production of recombinant plasmids
Steiert et al. A Gene Coding for a Membrane–Bound Hydrolase is Expressed as a Secreted, Soluble Enzyme in Streptomyces Lividans
EP0121352A1 (fr) Une séquence de guidage pour activer la sécrétion des produits à gènes
US6372479B1 (en) Fusarium sporotrichioides strains for production of B-carotene
Collins [20] Escherichia coli plasmids packageable in Vitro in λ bacteriophage particles
EP0373181B1 (fr) Nouvelle l-sorbosone deshydrogenase, coenzyme independante
Olsson et al. Molecular cloning of Bacillus sphaericus penicillin V amidase gene and its expression in Escherichia coli and Bacillus subtilis
US4649119A (en) Cloning systems for corynebacterium
US4987078A (en) Plasmid vectors for expression in Escherichia coli and/or Bacillus subtilis
US4828988A (en) Hybrid polypeptides comprising somatocrinine and alpha1 -antitrypsin, method for their production from bacterial clones and use thereof for the production of somatocrinine
US5082773A (en) Cloned streptococcal genes encoding protein G and their use to construct recombinant microorganisms to produce protein G
EP0317096A2 (fr) Vecteurs d'expression d'ADN recombinants et composés d'ADN codant pour l'isopénicilline-N-synthétase de streptomyces lipmanii
US5015574A (en) DNA sequence involved in gene expression and protein secretion, expression-secretion vector including the DNA sequence and the method of producing proteins by using the expression-secretion vector
Wu et al. Analysis of Escherichia coli K12 F factor transfer genes: traQ, trbA, and trbB
WO1986000929A1 (fr) Molecule d'adn recombinant, microorganismes transformes et procede de production de penicilline v amidase
Brusilow Proton leakiness caused by cloned genes for the F0 sector of the proton-translocating ATPase of Escherichia coli: requirement for F1 genes
CA2015046C (fr) Adn recombinant et vecteur d'expression
US5721137A (en) Plasmid vector and its use for the production of heterologous proteins
CA1275954C (fr) Fragments augmentant l'expression en 3' et methode
US5830720A (en) Recombinant DNA and expression vector for the repressible and inducible expression of foreign genes
JPH05284973A (ja) 組換プラスミドおよびこれをベクターとして用いる異種蛋白質の分泌生産方法
Mandrand-Berthelot et al. Construction and expression of hybrid plasmids containing the structural gene of the Escherichia coli K-12 3-deoxy-2-oxo-D-gluconate transport system
US5766881A (en) Induction-free process for the recombinant preparation of glutarylamidase

Legal Events

Date Code Title Description
AK Designated states

Designated state(s): DK JP US

AL Designated countries for regional patents

Designated state(s): AT BE CH DE FR GB IT NL SE

WWE Wipo information: entry into national phase

Ref document number: 1985903887

Country of ref document: EP

WWP Wipo information: published in national office

Ref document number: 1985903887

Country of ref document: EP

WWW Wipo information: withdrawn in national office

Ref document number: 1985903887

Country of ref document: EP

点击 这是indexloc提供的php浏览器服务，不要输入任何密码和下载